Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins

Marzieh Salehi, Benedikt A. Aulinger, David A. D'Alessio

Research output: Contribution to journalReview article

80 Scopus citations

Abstract

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

Original languageEnglish (US)
Pages (from-to)367-379
Number of pages13
JournalEndocrine Reviews
Volume29
Issue number3
DOIs
StatePublished - May 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins'. Together they form a unique fingerprint.

  • Cite this